



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. A31386-A (070165.0593)	Serial No. 09/855,886
	Applicant Coller et al. ATTACH TO #12	
	Filing Date May 15, 2001	Group Art Unit 1642
	Examiner Helms, L.	

.U.S. PATENT DOCUMENTS

*Exam. Init.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.

FOREIGN PATENT DOCUMENTS

No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

No.	
62.	Trikha et al., "Multiple Roles for Platelet GPIIb/IIIa and $\alpha_v\beta_3$ Integrins in Tumor Growth, Angiogenesis, and Metastasis," Cancer Res. 2002; 62:2824-2833.
63.	Trikha et al., "Platelets and Cancer: Implications for Antiangiogenic Therapy," Seminars in Thrombosis and Hemostasis 2002; 28:39-44.
64.	Cohen et al., "Potential Future Clinical Applications for the GPIIb/IIIa Antagonist, Abciximab in Thrombosis, Vascular and Oncological Indications," Pathol. Oncol. Res. 2000; 6(3):163-174.
65.	Coller, "Potential non-glycoprotein IIb/IIIa effects of abciximab," Am. Heart J. 1999; 138:S1-S5.
66.	Luna et al., "Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model." Lab. Invest. 1996; 75:563-573.

NY02:431027.1

Examiner

Date Considered

8/18/03